Quince Therapeutics gets Nasdaq notice over equity shortfall
Nasdaq notified Quince Therapeutics it failed Listing Rule 5450(b)(1)(A) after stockholders’ equity of ($35.3M), below the $10M minimum. Shares continue on Nasdaq Global Select Market under QNCX; company has until October 15, 2026 to submit a compliance plan.
On August 31, 2026, the company said it received notice from Nasdaq that it was out of compliance with Listing Rule 5450(b)(1)(A) because stockholders' equity was ($35.3M), below the $10M minimum. Trading on the Nasdaq Global Select Market continues under QNCX, and the company has until October 15, 2026 to submit a compliant plan.